Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and the potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the Group is expected to record a loss for the six months ended 30 June 2017 as compared with the net profit recorded for the corresponding period of last year.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by Universal Health International Group Holding Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

The board of directors (the "**Directors**") of the Company (the "**Board**") wishes to inform the shareholders and the potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the Group is expected to record a loss for the six months ended 30 June 2017 (the "**Period**") as compared with the net profit recorded for the corresponding period of last year. Details will be disclosed in the results announcement to be issued soon.

The expected loss recorded for the Period was mainly due to the following factors:

(i) In respect of the macro aspect: the new round of the Northeast Area Revitalization Plan in the People's Republic of China（中華人民共和國東北地區振興規劃）is now in an early stage, which intensifies the competition in the pharmaceutical circulation market and affects the consuming capacity, resulting in a decrease in overall sales volume of the Group.

(ii) In respect of the micro aspect: during the Period, the Group has applied various promotion measures, such as more member activities and various promotion activities to provide discounts to the customers, in order to mitigate the significant decrease in sales volume and to maintain relative competitiveness, which resulted in a decrease in the gross margin of the Group for the Period.

Though the Group is expected to record a loss for the Period, the Board is of the view that the overall financial position of the Group remains healthy while the Group will facilitate proactively its strategic transformation, promote the development of the partnership mechanism, the construction of "Universal Health^{+}" platform and the diversified breakthrough models, and cut down the logistics distribution for products of low benefit so as to enhance the structural upgrade; and will constantly implement measures to improve the cohesion of the management and core staff and maintain the competitiveness, and therefore the Board is optimistic about the long term outlook of the Group.

The information contained in this announcement is prepared only based on the Board's preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, but not on any data or information which has been audited or reviewed by the auditors of the Company. The Company is still finalizing the audited results of the Group for the Period and will disclose the results in the results announcement to be published in August 2017.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Universal Health International Group Holding Limited
Jin Dongtao
Chairman

Hong Kong, 25 July 2017

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Sun Libo; and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.